Literature DB >> 18751937

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

J A Kanis1, E V McCloskey, H Johansson, O Strom, F Borgstrom, A Oden.   

Abstract

UNLABELLED: Assessment and intervention thresholds are developed and proposed in men aged over 50 years and postmenopausal women for the UK based on fracture probability from the WHO fracture risk assessment tool (FRAX).
INTRODUCTION: The FRAX tool has recently become available to compute the 10-year probability of fractures in men and women from clinical risk factors (CRFs) with or without the measurement of femoral neck bone mineral density (BMD). The aim of this study was to develop a case-finding strategy for men and women from the UK at high risk of osteoporotic fracture by delineating the fracture probabilities at which BMD testing or intervention should be recommended.
METHODS: Fracture probabilities were computed using the FRAX tool calibrated to the epidemiology of fracture and death in the UK. The relationship between cost effectiveness and fracture probability used the source data from a prior publication that examined the cost effectiveness of generic alendronate in the UK. An intervention threshold was set by age in men and women, based on the fracture probability equivalent to that of women with a history of a prior osteoporosis related fracture. In addition, assessment thresholds for the use of BMD testing were explored. Assessment thresholds for the measurement of BMD followed current practice guidelines where individuals were considered to be eligible for assessment in the presence of one or more CRF. An upper assessment threshold (i.e. a fracture probability above which patients could be treated without recourse to BMD) was based on optimisation of the positive predictive value of the assessment tool. The consequences of assessment and intervention thresholds on the requirement for BMD test and interventions were assessed using the distribution of clinical risk factors and femoral neck BMD for women in the source cohorts used for the development of the FRAX models
RESULTS: Treatment was cost effective at all ages when the 10-year probability of a major fracture exceeded 7%. The intervention threshold at the age of 50 years corresponded to a 10-year probability of a major osteoporotic fracture of 7.5%. This rose progressively with age to 30% at the age of 80 years, so that intervention was cost effective at all ages. Assessment thresholds for testing with BMD (6-9% at the age of 50 years) also rose with age (18-36% at the age of 80 years). The use of these thresholds in a case-finding strategy would identify 6-20% of women as eligible for BMD testing and 23-46% as eligible for treatment, depending on age. The same threshold can be used in men.
CONCLUSION: The study provides a method of developing management algorithms for osteoporosis from the estimation of fracture probabilities, rather than those based on BMD alone or BMD with single or multiple CRFs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18751937     DOI: 10.1007/s00198-008-0712-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  41 in total

Review 1.  Treatment of established osteoporosis: a systematic review and cost-utility analysis.

Authors:  J A Kanis; J E Brazier; M Stevenson; N W Calvert; M Lloyd Jones
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

2.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

Authors:  J A Kanis; P Delmas; P Burckhardt; C Cooper; D Torgerson
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

Authors:  J A Kanis; M Stevenson; E V McCloskey; S Davis; M Lloyd-Jones
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

4.  Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.

Authors:  J A Kanis; I P Barton; O Johnell
Journal:  Osteoporos Int       Date:  2004-07-23       Impact factor: 4.507

5.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

6.  Alcohol intake as a risk factor for fracture.

Authors:  John A Kanis; Helena Johansson; Olof Johnell; Anders Oden; Chris De Laet; John A Eisman; Huibert Pols; Alan Tenenhouse
Journal:  Osteoporos Int       Date:  2004-09-29       Impact factor: 4.507

7.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

Review 8.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

9.  Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

Authors:  Eugene McCloskey; Peter Selby; Mike Davies; John Robinson; Roger M Francis; Judith Adams; Karthik Kayan; Monique Beneton; Tarja Jalava; Liisa Pylkkänen; Juha Kenraali; Sakari Aropuu; John A Kanis
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741

10.  A family history of fracture and fracture risk: a meta-analysis.

Authors:  J A Kanis; H Johansson; A Oden; O Johnell; C De Laet; J A Eisman; E V McCloskey; D Mellstrom; L J Melton; H A P Pols; J Reeve; A J Silman; A Tenenhouse
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

View more
  184 in total

1.  Can self-reported height and weight be used to calculate 10 year risk of osteoporotic fracture?

Authors:  M J Bridges; S Ruddick
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  An increased risk for fractures: another cause of frailty in HIV-infected subjects.

Authors:  Carmine Gazzaruso
Journal:  Endocrine       Date:  2012-06       Impact factor: 3.633

Review 3.  Development and use of FRAX in osteoporosis.

Authors:  J A Kanis; E V McCloskey; H Johansson; A Oden; O Ström; F Borgström
Journal:  Osteoporos Int       Date:  2010-05-13       Impact factor: 4.507

4.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

Review 5.  Assessment of fracture risk.

Authors:  Sanford Baim; William D Leslie
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

Review 6.  The epidemiology of osteoporosis.

Authors:  Michael A Clynes; Nicholas C Harvey; Elizabeth M Curtis; Nicholas R Fuggle; Elaine M Dennison; Cyrus Cooper
Journal:  Br Med Bull       Date:  2020-05-15       Impact factor: 4.291

7.  Prevalence of fracture and osteoporosis risk factors in American Indian and Alaska Native people.

Authors:  Tracy Frech; Khe-ni Ma; Elizabeth D Ferrucci; Anne P Lanier; Molly McFadden; Lillian Tom-Orme; Martha L Slattery; Maureen A Murtaugh
Journal:  J Health Care Poor Underserved       Date:  2012-08

8.  FRAX-based intervention and assessment thresholds for osteoporosis in Iran.

Authors:  P Khashayar; A Keshtkar; A Ostovar; B Larijani; H Johansson; N C Harvey; M Lorentzon; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2019-08-01       Impact factor: 4.507

9.  Should there be a fracas over FRAX and other fracture prediction tools?: Comment on "A comparison of prediction models for fractures in older women".

Authors:  Cathleen S Colón-Emeric; Kenneth W Lyles
Journal:  Arch Intern Med       Date:  2009-12-14

10.  Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Authors:  O Ström; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2012-12-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.